Month: December 2021

Does Your Personality Make You More Likely to be Scammed

Posted on by Admin

Why Some are More Vulnerable to Financial Scams

 

Can attitudes, beliefs, even politics impact whether a person is more likely to fall for a financial scam? The short answer is “yes.”  After a two-year study, researchers have learned which key personality traits cause one person to be more likely to be scammed than another. Knowing yourself and the traits or “mental frames” defined in the research may help prevent you from falling for a well-designed scam.

The FINRA Investor Education Foundation (FINRA Foundation), Better Business Bureau (BBB) Institute for Marketplace Trust, and the University of Minnesota are responsible for the study titled, Exposed to
Scams: Can Challenging Consumers’ Beliefs Protect Them from Fraud?

The Study

Participants were chosen from Better Business Bureau report complaints filed on BBB Scam TrackerSM. Researchers gathered study data throughout 2017 and 2018 and conducted interviews.

Investigators found that attitudes and beliefs shaping the way study participants looked at the world, known as “mental frames,” may have influenced the way they reacted to scams. Specifically, researchers propose that mental frames governing four attributes, Compliance, Opportunity, Intelligence, and Order may have influenced how the scammed interviewees interpreted what scammers told them.

Compliance – Belief that authority and institutions yield power over the individual.

Expectations that authorities can enact sanctions and limit the freedoms of individuals had the more likely scammed to believe that authority should not be challenged.

Opportunity – Wealth is built on random opportunities.

The thought that the world is organized in a way that rewards good people. Asking too many questions can make a person seem ignorant.

Intelligence – Not knowing the answers causes shame and reduces an individual’s status.

Perceived lack of intelligence can affect an individual’s sense of power and impact.

Order – The natural order of things is benevolent and just.

Individuals who do good will be rewarded and those who do bad will be punished.

Mental frames, according to the study, may determine how and why some people lose money to fraud. The concept is based on the theory that all human learning, whether formal or informal, is socially based. And human response to life events is shaped by perception of reality, which reflects what we have learned from our schooling, our experiences, and our interactions with others. So, whether subconsciously or consciously, mental frames guide thinking and reactions to money, people, power, authority, and other aspects of life.

 

Mental Frames and Financial Fraud

The study was designed to identify the mental frames that may cause people to lose money to financial fraudsters. Researchers wondered if identifiable mental frames might lead people to overlook red flags and inconsistencies in a scammer’s appeal. Similarly, they wondered if mental frames could protect individuals by motivating them to question the situation or reject the scammer’s pitch. Understanding why someone avoids scams offers hope to protect the broader population.

Part of the mental framework that is most vulnerable is the desire to believe that good things actually do happen to good people. And, that good individuals are protected from undeserved harm. People who believe in a just world may ignore the warning signs of something that should seem too good to be true. When this optimism is paired with a mental frame that suggests wealth is a zero-sum game, the individual may have trouble seeing the warning signs of a scam.

These four mental frames play out in different ways in different people. One frame may take precedence over the others, or the effects of two or three mental frames may come together to strongly influence the individual’s response to the scam.

“This research gives us new ways to understand who is at risk for losing money to financial scams and opens novel possibilities for protecting people against different forms of fraud,” said FINRA Foundation President Gerri Walsh. “We hope these insights into the role that beliefs and attitudes play in fraud victimization will stimulate additional research and the development of effective strategies to reduce consumer losses.”

Take-Away

The mental frames defined above are noble characteristics to have. However, when dealing with someone that calls by phone, perhaps pretending they are with the IRS, it can for some be difficult for many to push back and be consistent with who they are. Knowledge of this study’s results, coupled with a good look at one’s own mindset, could cause one to pause, think, and avoid making an expensive mistake.

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading:



Will Companies that Make Covid Test Kits Rally?

Can Market Strength Last into 2022?





Since 2008, Monetary Policy Has Cost American Savers about $4 Trillion

FinTech Pirates are Looting Unsuspecting Trading Accounts

 

Source:

https://www.finrafoundation.org/sites/finrafoundation/files/exposed-to-scams-can-challenging-consumers-beliefs-protect-them-from-fraud.pdf

 

 

 

Stay up to date. Follow us:

 

The Channelchek Articles Investors Devoured in 2021

Posted on by Admin

Channelchek’s Top Stories and Topics of 2021

 

During 2021 the interest you’ve shown has been in investment topics as diverse as SPACs, cannabis, sustainable investing, biotech, CFA exams, and a host of others. We reviewed the top articles readers read more than the others during 2021. Among the top, we discovered a few recurring topics that appealed to readers. And also a few standalone topics that surprised us.

We’re always looking for input as to what information you’d like to see more of. At the bottom of this article, feel free to click on my name to email any thoughts or suggestions you may have.

Electric vehicles were a popular topic among our readers in 2021. The increased focus on sustainable investing along with government money helping manufacturers kept investor interest high in all related topics, including mining for copper, lithium, and rare earth minerals. The title to one of our top articles asks the question, Will U.S. Car Companies be Handed Different EV Advantages? As the title implies, it discusses Tesla (TSLA), Ford (F), and General Motors (GM), and incentives from Washington.

Another popular topic was Michael Burry’s Tweets.  The hedge fund manager more than once expressed a strong opinion, usually non-mainstream, it would create a flurry of comments, then after a few hours, he’d delete his blue-checkmark Twitter account.  One of these articles is titled Michael Burry is Tweeting About the Markets and His Subpoena. One of the key discussions in this article is Burry’s Tweet linked to a research paper. The research demonstrated that the US stock market’s value rose by $5 for every $1 invested in it. Another Popular Channelchek Burry article is titled, Michael Burry Tweets Advice on Cryptocurrencies, Stocks, Inflation, and Government Bailouts – Then Bails Out the topics covered in this interesting read are all explained in the longwinded title. While there were other well-read articles on this subject, only one other made it into our top ten. This one pitted Dr. Burry against Cathie Wood of Ark Invest. The title is Michael Burry vs Cathie Wood is Not an Even Competition.

The inspiration for this last one was Burry’s firm Scion Capital Management’s 13F filing showed a short position worth $30.8 million on Wood’s  Ark Investments, Innovation ETF (ARKK). The article explains the position and defines the difference between an active ETF fund manager and a hedge fund manager.

Cathie Woods is a very transparent CIO and recognizable public figure, so it’s no surprise she made this list more than once. In 2021, and still ongoing, the Chinese government acted to change the playing field on Chinese companies trading on overseas exchanges. We published an article mostly centered on restrictions placed on video game producers in China that put capitalism in a positive light. Wood’s reaction is worth reading and understanding in, China’s New Rules on Some Public Companies has Cathie Wood and Others Adjusting Portfolios.

Inflation was a hot topic in the second half of the year and continues to be. Barely a week had gone by where I didn’t feel compelled to share mounting data on price concerns. In late October, someone on the team came across a newsletter installment from Frank Holmes of U.S. Global Investors (GROW), we all agreed it was worthy of sharing with our readers.  Inflation Is Eating Your Lunch If You’re Doing This One Common Thing became one of our top ten most-read articles of the year.

The only other article to make it into the top ten not authored by in-house editors is, Understanding the
Robinhood Class Action Lawsuit. No-nonsense analysis of the four “Causes of Action” in the class action complaint against Robinhood (HOOD) was hard to come by. We brought in an attorney to go through all the legal filings and breakdown, in writing, the intricacies at play. Judging by how often the article was shared on social media, it was appreciated.

Cryptocurrency had a big year in 2021. Channelchek provides regular research on a number of Blockchain-related companies. While expert analysis on cryptocurrencies or other blockchain products are outside of the stock market and are not part of our mission, we write on the subject because what happens to crypto, impacts the publicly traded companies that bring it to life. There were multiple top ten articles in this category. These include, What’s Inside
the Cryptocurrency Bill.

Another article centered around Cathie Wood, this time with Elon Musk and Jack Dorsey titled, Elon Musk, Jack Dorsey, and Cathie Wood Drop Bombshells at Bitcoin Conference was a top story. Prices surged on cryptos as the “A-Team” presenters shared their expertise and expectations for the future at the B-Word Conference.

Uranium became a hot investment during the year as the yellow metal became more acceptable to sustainability investors. With a growing shortage of 24/7 reliable power, and new style reactors coming on-line uranium investing got a lot of attention. An ETF that held physical uranium was even created and was met with such great demand that the price of uranium trended up as more deposits into the ETF meant more uranium purchases by the manager. Another article that featured highly recognized names was written about a new design of a nuclear reactor. The Bill Gates
/ Warren Buffett Natrium Reactor Risks and Benefits article may have introduced many investors to this new reimagined power plant.

Small and microcap stocks are the focus of Channelchek. So it comes as no surprise that it is the focus of many of our readers. Each year we cover the Russell 2000 Index reconstitution with play-by-play articles to keep you aware of what to expect and the likely inclusions and exclusions from the small-cap index. In 2021 two of these articles were read broadly enough to be among our most popular articles. Look for new Russell reconstitution articles beginning in early May of 2022. Last year’s favorites were, The Annual
Russell Index Revision and Dates to Watch, and FTSE Russell Inaccuracies and Changes Before Final Adjustment.

No one will be surprised when the year ahead turns out to be full of surprises. Channelchek registered users get regular emails full of pertinent articles, top-tier equity research, and video content to bring CEOs onto your desktop or into the palm of your hand. If you haven’t taken advantage of our free premium, take a moment now to add us now and make 2022 an even more informed New Year.

Have a Happy New Year,

 

Paul Hoffman

Managing Editor, Channelchek

 

 

Stay up to date. Follow us:

 

Garibaldi Resources (GGIFF)(GGI:CA) – Setting Up for a Productive 2022

Posted on by Admin

Friday, December 31, 2021

Garibaldi Resources (GGIFF)(GGI:CA)
Setting Up for a Productive 2022

Garibaldi Resources Corp is a Canadian-based junior exploration company. It is engaged in the acquisition, exploration, and evaluation of mineral properties located in Canada and Mexico. The company’s projects in Mexico include the La Patilla, the Rodadero, the Tonichi and the Iris project. Its projects in Canada include the PSP and King projects, The Cariboo Copper and Gold project, the Red Lion project, the Grizzly project, the Tora Tora project and the Black Gold project.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Final ZTEM interpretation expected shortly. Garibaldi awaits a final 3-D Z-Axis Tipper electromagnetic (ZTEM) interpretation of a survey completed over the entire Eskay Claim Group. Preliminary 2-D ZTEM survey data identified targets across the E&L and Palm Springs property. The ZTEM survey will help to define, rank, and prioritize deeper conductive anomalies.

    Updating estimates.  We have updated our estimates to incorporate recently reported financial results for the quarter ended October 31, 2021. As an exploration company, Garibaldi Resources does not generate revenue and incurs expenses to fund exploration and drilling programs at its various projects. For the three months ended October 31, Garibaldi Resources reported a net loss of …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Does Your Personality Make You More Likely to be Scammed?

Posted on by Admin

Why Some are More Vulnerable to Financial Scams

 

Can attitudes, beliefs, even politics impact whether a person is more likely to fall for a financial scam? The short answer is “yes.”  After a two-year study, researchers have learned which key personality traits cause one person to be more likely to be scammed than another. Knowing yourself and the traits or “mental frames” defined in the research may help prevent you from falling for a well-designed scam.

The FINRA Investor Education Foundation (FINRA Foundation), Better Business Bureau (BBB) Institute for Marketplace Trust, and the University of Minnesota are responsible for the study titled, Exposed to
Scams: Can Challenging Consumers’ Beliefs Protect Them from Fraud?

The Study

Participants were chosen from Better Business Bureau report complaints filed on BBB Scam TrackerSM. Researchers gathered study data throughout 2017 and 2018 and conducted interviews.

Investigators found that attitudes and beliefs shaping the way study participants looked at the world, known as “mental frames,” may have influenced the way they reacted to scams. Specifically, researchers propose that mental frames governing four attributes, Compliance, Opportunity, Intelligence, and Order may have influenced how the scammed interviewees interpreted what scammers told them.

Compliance – Belief that authority and institutions yield power over the individual.

Expectations that authorities can enact sanctions and limit the freedoms of individuals had the more likely scammed to believe that authority should not be challenged.

Opportunity – Wealth is built on random opportunities.

The thought that the world is organized in a way that rewards good people. Asking too many questions can make a person seem ignorant.

Intelligence – Not knowing the answers causes shame and reduces an individual’s status.

Perceived lack of intelligence can affect an individual’s sense of power and impact.

Order – The natural order of things is benevolent and just.

Individuals who do good will be rewarded and those who do bad will be punished.

Mental frames, according to the study, may determine how and why some people lose money to fraud. The concept is based on the theory that all human learning, whether formal or informal, is socially based. And human response to life events is shaped by perception of reality, which reflects what we have learned from our schooling, our experiences, and our interactions with others. So, whether subconsciously or consciously, mental frames guide thinking and reactions to money, people, power, authority, and other aspects of life.

 

Mental Frames and Financial Fraud

The study was designed to identify the mental frames that may cause people to lose money to financial fraudsters. Researchers wondered if identifiable mental frames might lead people to overlook red flags and inconsistencies in a scammer’s appeal. Similarly, they wondered if mental frames could protect individuals by motivating them to question the situation or reject the scammer’s pitch. Understanding why someone avoids scams offers hope to protect the broader population.

Part of the mental framework that is most vulnerable is the desire to believe that good things actually do happen to good people. And, that good individuals are protected from undeserved harm. People who believe in a just world may ignore the warning signs of something that should seem too good to be true. When this optimism is paired with a mental frame that suggests wealth is a zero-sum game, the individual may have trouble seeing the warning signs of a scam.

These four mental frames play out in different ways in different people. One frame may take precedence over the others, or the effects of two or three mental frames may come together to strongly influence the individual’s response to the scam.

“This research gives us new ways to understand who is at risk for losing money to financial scams and opens novel possibilities for protecting people against different forms of fraud,” said FINRA Foundation President Gerri Walsh. “We hope these insights into the role that beliefs and attitudes play in fraud victimization will stimulate additional research and the development of effective strategies to reduce consumer losses.”

Take-Away

The mental frames defined above are noble characteristics to have. However, when dealing with someone that calls by phone, perhaps pretending they are with the IRS, it can for some be difficult for many to push back and be consistent with who they are. Knowledge of this study’s results, coupled with a good look at one’s own mindset, could cause one to pause, think, and avoid making an expensive mistake.

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading:



Will Companies that Make Covid Test Kits Rally?

Can Market Strength Last into 2022?





Since 2008, Monetary Policy Has Cost American Savers about $4 Trillion

FinTech Pirates are Looting Unsuspecting Trading Accounts

 

Source:

https://www.finrafoundation.org/sites/finrafoundation/files/exposed-to-scams-can-challenging-consumers-beliefs-protect-them-from-fraud.pdf

 

 

 

Stay up to date. Follow us:

 

Reddit Comments and Their Influence on Cannabis Laws

Posted on by Admin 


	Image Credit: Governor Tom Wolf, (Flickr)

Have Reddit Posts Been Paving the Way for State Marijuana Reform?

 

Could Reddit, which came into existence in 2005, be a powerful reason U.S. support for marijuana legalization grew from 38% to 65% from 2008-2019? A 275-page academic paper was just made available that studies the discourse that preceded and followed the shift in attitudes. It makes a case that changes in public sentiment can be attributed to what is posted on Reddit. This sentiment can work its way into new legislative efforts. The research work also identifies what type of conversations had the most influence on shifting public support of marijuana legalization.

The researcher from Brown University compiled more than three million Reddit comments from 2009 to 2019 and then used machine learning to analyze the interactions.  His method of analysis was designed to first separate the comments into categories (for example, anecdotal vs. generalized comments) and then better understand the more persuasive online conversations. The conversations came from a broad swath of subreddits that the researcher deemed diverse enough for an accurate study.

 

The frequency of comments from the 15 most frequent subreddits in the corpus

 

The research was part of a Ph.D. dissertation by Ph.D. candidate Babak Hemmatian Borujeni. The paper was titled “Taking the High
Road: A Big Data Investigation of Natural Discourse in the Emerging U.S.
Consensus about Marijuana Legalization” In his research, he uncovers empirically-based truths that may surprise non-social media users.  One such truth is that while historically, sharing personal anecdotes and experiences has been a major factor in changing one’s strongly held viewpoint, this is less true today with social media. Instead, people posting more generalized, character judgment-based arguments was a more clear factor when impacting state-level cannabis reform measures. “Anecdotes were less often used to persuade people, meaning their persuasive potential was somewhat wasted,” Hemmatian said. “Still, people did often briefly mention them to buttress more general claims like the mentioned character judgments.”

An increase in character judgments and assertions about people’s attributes, like whether being a prohibitionist makes someone a bad person, commonly preceded state legalization efforts, particularly around 2012 as the first states moved to end prohibition, the study found.

There were some other interesting themes identified in the study. For example, discussions of the health impacts of cannabis “only picked up after legalization was all but over, and only in casual conversations.” Legal implications of reform, meanwhile, “were not prominently discussed even after legalization had succeeded in most states.” This would seem peculiar as, “Both topics are highly relevant to whether and how the substance should be de-regulated, but were ignored in decision-making and at best attended to once the societal decision was already made,” the author said.

The study emphasizes that character judgments were the main factor but also pointed out that it was not a strong change agent. It was able to persuade those that were more indifferent, not those strictly opposed. “While not the most persuasive approach according to previous research, character judgments may have still pushed people who were on the fence but not diametrically opposed to legalization over to the pro-legalization camp,” he wrote. “This is because they highly simplify decision-making: One no longer needs to know the complicated effects of cannabis on health, the economy and the society to make up their mind; they just need to think through their personal moral principles. This may have been comforting during a transition period when the uncertainty surrounding marijuana’s status would have been anxiety-inducing for many folks.”

The broad conclusion of the study is that “early legalization victories depended on character judgments while the final nails were hammered into prohibition’s coffin with Plot-focused strategies revolving around politics and crime.” The paper explains, “The shift happened entirely within the generalized portion of the discourse, meaning that a non-compositional approach to frame classification would have missed it.”

 

Others Gaining Insight from Social Media

Ph.D. candidates aren’t the only ones mining information from social media posts.  Recently the Food and Drug Administration (FDA) announced that it plans to use Reddit and other “novel” data sources to gain a better understanding of public health issues surrounding the use of CBD and other “emerging” marijuana derivatives like delta-8 THC. The agency also wants to develop a system of finding “safety signals and usage patterns associated with emerging CDPs in real-time.” This includes Delta-8, a cannabinoid that may have been overlooked legislatively in many states, and placed in the general category of CBD without evaluation as to safety and efficacy.

Paul Hoffman

Managing Editor, Channelchek

 



What is the Approval Process for Medical Devices?

Will Companies that Make Covid Test Kits Rally?





Attend Paris Hilton’s Metaverse NYE Party

Cannabis Customers Served by the Ice Cream Truck Delivery Model

 

Sources:

https://www.researchgate.net/publication/356109604_Taking_the_High_Road_A_Big_Data_Investigation_of_Natural_Discourse_in_the_Emerging_US_Consensus_about_Marijuana_Legalization

https://www.fda.gov/media/153183/download

https://www.marijuanamoment.net/researcher-uses-reddit-to-learn-what-kinds-of-marijuana-posts-influenced-legalization-attitudes/

 

Stay up to date. Follow us:

 

Bunker Hill Announces Filing of Updated Technical Report

Posted on by Admin



Bunker Hill Announces Filing of Updated Technical Report

Research, News, and Market Data on Bunker Hill Mining

 

TORONTO, Dec. 29, 2021 (GLOBE NEWSWIRE) — Bunker Hill Mining Corp. (the “Company”) (CSE: BNKR, OTCQB: BHLL) is pleased to announce the filing of an independent Technical Report (“Technical Report”), containing an updated Mineral Resource Estimate for the Bunker Hill Mine in the world-class Silver Valley region of Idaho, USA.

The Technical Report, dated December 29, 2021 and entitled “Technical Report And Preliminary Economic Assessment For Underground Milling and Concentration of Lead, Silver and Zinc at the Bunker Hill Mine, Coeur d’Alene Mining District, Shoshone County, Idaho, USA” with an effective date of November 29, 2021, was prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”).

The Company’s news release (“Prior News Release”) dated November 30, 2021 (entitled “ Bunker Hill Announces Mineral Resource Update, Including 59% Increase in M&I to 1.1 Billion Zinc Eq Pounds at Higher Grades ”) summarizes key results, assumptions and estimates contained in the Technical Report with respect to the updated Mineral Resource Estimate. There are no differences between the key results, assumptions and estimates contained in the Technical Report and the Prior News Release.

The preliminary economic assessment (“PEA”) contained in the Technical Report is unchanged from the PEA contained in the technical report dated June 4, 2021 and entitled, “Technical Report and Preliminary Economic Assessment for Underground Milling and Concentration of Lead, Silver and Zinc at the Bunker Hill Mine, Coeur d’Alene Mining District, Shoshone County, Idaho, USA” with an effective date of April 19, 2021.

The PEA is preliminary in nature and includes inferred mineral resources that are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as mineral reserves, and there is no certainty that the PEA will be realized.

The Technical Report is available on our website at www.bunkerhillmining.com and has been filed on SEDAR under the Company’s issuer profile at www.sedar.com .

QUALIFIED PERSON

Mr. Scott E. Wilson, CPG, President of RDA and a consultant to the Company, is an independent “qualified person” as defined by NI 43-101 and is acting as the qualified person for the Company. He has reviewed and approved the technical information summarized in this news release.

Dr. Deepak Malhotra, SME of Pro Solv LLC, is an independent “qualified person” as defined by NI 43-101 and has approved the metallurgical data utilized in the updated Technical Report and Mineral Resource Estimate.

MineTech developed the mine infrastructure, capital expenditures and operating expenditures related portions of the PEA, as well as portions of the mine plan and operating schedules in coordination with RDA and Pro Solv Consulting, LLC. Robert Todd, P.E. is a Principal of MineTech, a registered engineer in Idaho, consultant to the Company and an independent “qualified person” as defined by NI 43-101.

The qualified persons have verified the information disclosed herein, including the sampling, preparation, security and analytical procedures underlying such information, and are not aware of any significant risks and uncertainties that could be expected to affect the reliability or confidence in the information discussed herein.

ABOUT BUNKER HILL MINING CORP.

Under new Idaho-based leadership the Bunker Hill Mining Corp, intends to sustainably restart and develop the Bunker Hill Mine as the first step in consolidating a portfolio of North American precious-metal assets with a focus on silver. Information about the Company is available on its website, www.bunkerhillmining.com, or within the SEDAR and EDGAR databases.

For additional information contact:

David Wiens, CFA

CFO & Corporate Secretary

+1 208 370 3665

ir@bunkerhillmining.com

Cautionary Statements

Certain statements in this news release are forward-looking and involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, as well as within the meaning of the phrase ‘forward-looking information’ in the Canadian Securities Administrators’ National Instrument 51-102 – Continuous Disclosure Obligations. Forward-looking statements are not comprised of historical facts. Forward-looking statements include estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to the Company, the Company provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information.

Forward looking information in this news release includes, but is not limited to, the Company’s intentions regarding its objectives, goals or future plans and statements. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to: the ability to predict and counteract the effects of COVID-19 on the business of the Company, including but not limited to the effects of COVID-19 on the price of commodities, capital market conditions, restriction on labour and international travel and supply chains; failure to identify mineral resources; failure to convert estimated mineral resources to reserves; the inability to complete a feasibility study which recommends a production decision; the preliminary nature of metallurgical test results; the Company’s ability to restart and develop the Bunker Hill Mine and the risks of not basing a production decision on a feasibility study of mineral reserves demonstrating economic and technical viability, resulting in increased uncertainty due to multiple technical and economic risks of failure which are associated with this production decision including, among others, areas that are analyzed in more detail in a feasibility study, such as applying economic analysis to resources and reserves, more detailed metallurgy and a number of specialized studies in areas such as mining and recovery methods, market analysis, and environmental and community impacts and, as a result, there may be an increased uncertainty of achieving any particular level of recovery of minerals or the cost of such recovery, including increased risks associated with developing a commercially mineable deposit with no guarantee that production will begin as anticipated or at all or that anticipated production costs will be achieved; failure to commence production would have a material adverse impact on the Company’s ability to generate revenue and cash flow to fund operations; failure to achieve the anticipated production costs would have a material adverse impact on the Company’s cash flow and future profitability; delays in obtaining or failures to obtain required governmental, environmental or other project approvals; political risks; changes in equity markets; uncertainties relating to the availability and costs of financing needed in the future; the inability of the Company to budget and manage its liquidity in light of the failure to obtain additional financing, including the ability of the Company to complete the payments pursuant to the terms of the agreement to acquire the Bunker Hill Mine Complex; inflation; changes in exchange rates; fluctuations in commodity prices; delays in the development of projects; capital, operating and reclamation costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry; and those risks set out in the Company’s public documents filed on SEDAR. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Cautionary Note to United States Investors Concerning Estimates of Measured, Indicated and Inferred Resources

This press release has been prepared in accordance with the requirements of the securities laws in effect in Canada, which differ from the requirements of U.S. securities laws. Unless otherwise indicated, all resource and reserve estimates included in this press release have been disclosed in accordance with NI 43-101 and the Canadian Institute of Mining, Metallurgy, and Petroleum Definition Standards on Mineral Resources and Mineral Reserves. NI 43-101 is a rule developed by the Canadian Securities Administrators which establishes standards for all public disclosure an issuer makes of scientific and technical information concerning mineral projects. Canadian disclosure standards, including NI 43-101, differ significantly from the requirements of the United States Securities and Exchange Commission (“SEC”), and resource and reserve information contained in this press release may not be comparable to similar information disclosed by U.S. companies. In particular, and without limiting the generality of the foregoing, the term “resource” does not equate to the term “reserves”. Under U.S. standards, mineralization may not be classified as a “reserve” unless the determination has been made that the mineralization could be economically and legally produced or extracted at the time the reserve determination is made. The SEC’s disclosure standards normally do not permit the inclusion of information concerning “measured mineral resources”, “indicated mineral resources” or “inferred mineral resources” or other descriptions of the amount of mineralization in mineral deposits that do not constitute “reserves” by U.S. standards in documents filed with the SEC. Investors are cautioned not to assume that any part or all of mineral deposits in these categories will ever be converted into reserves. U.S. investors should also understand that “inferred mineral resources” have a great amount of uncertainty as to their existence and great uncertainty as to their economic and legal feasibility. It cannot be assumed that all or any part of an “inferred mineral resource” will ever be upgraded to a higher category. Investors are cautioned not to assume that all or any part of an “inferred mineral resource” exists or is economically or legally mineable. Disclosure of “contained ounces” in a resource is permitted disclosure under Canadian regulations; however, the SEC normally only permits issuers to report mineralization that does not constitute “reserves” by SEC standards as in-place tonnage and grade without reference to unit measures. The requirements of NI 43-101 for disclosure of “reserves” are also not the same as those of the SEC, and reserves disclosed by the Company in accordance with NI 43-101 may not qualify as “reserves” under SEC standards. Accordingly, information concerning mineral deposits contained in our website may not be comparable with information made public by companies that report in accordance with U.S. standards.

Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN™ (BBV152), COVID-19 Candidate Vaccine, in Children 2 – 18 YEARS

Posted on by Admin



Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN™ (BBV152), COVID-19 Candidate Vaccine, in Children 2 – 18 YEARS

 

Research, News, and Market Data on Ocugen

 

  • COVAXIN™ whole virus inactivated vaccine generated broad antibody response comparable to those seen in a large phase 3 trial in adults 18+
  • Adverse events were primarily mild, and no serious adverse events (SAEs) were noted
  • Immunobridging trial demonstrated safety, reactogenicity and immunogenicity of COVAXIN™ in children from 2 years old and up
  • No cases of myocarditis or blood clots were reported, as expected with inactivated vaccines

MALVERN, Pa., Dec. 30, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced today that its partner, Bharat Biotech, posted results from a Phase 2/3 trial conducted in India of candidate vaccine, COVAXIN™ (BBV152), in children, aged 2 – 18 years, demonstrating a robust neutralizing antibody response and favorable safety profile on the pre-print server, medRXiv. Using a two-dose regimen administered 28-days apart, antibody responses in subjects were comparable to adult data from a previous phase 3 study. Those results demonstrated a greater than 93% reduction in severe disease. These pediatric data were the basis of Ocugen’s pediatric Emergency Use Authorization (EUA) submission in the United States for children 2-18 on November 5, 2021.

“These data represent the first positive vaccine data in children as young as two years of age and come at an important time as COVID-19 infections are seeing a spike across the globe,” said Shankar Musunuri, PhD, MBA, Chairman of the Board, Chief Executive Officer and Co-Founder of Ocugen. “The results suggest that COVAXIN™, which is made on the same platform used in traditional polio pediatric vaccines for decades, when administered in a two-dose series to children between 2-18, may offer an option that is safe while delivering a robust immune response.”

In the study, immunogenicity against key COVID-19 proteins was measured using geometric mean titer (GMT), a test that measures the amount of antibodies in the blood in response to the presence of the virus. GMT was measured across three age groups and demonstrated strong immune response after the second dose. There were no serious adverse events such as myocarditis, pericarditis, or blood clots, reported in any of the three age groups.

This immunobridging trial was intended to determine if COVAXIN™ generates the same protective immunity in children as it does in adults. To be considered equivalent, pediatric participants needed to achieve comparable GMT’s to those generated by adults in a large phase 3 clinical trial. At Day 56, across all ages, the mean SARS-CoV-2 antibody GMT was more than 30% higher in children aged 2-18 than the mean GMT from Phase 3 clinical trial involving 25,800 adult subjects aged 18+. These data demonstrate children 2-18 generate antibody response comparable to adults fully vaccinated with COVAXIN™ (BBV152).

The study also showed increased antibody titers against 3 viral antigens (Spike – S1, Receptor Binding Domain – RBD and Nucleocapsid – NP) providing a broad immune response to COVID-19. In each case a more than 4-fold increase in neutralizing antibody titers versus baseline (titers measured in the same participants before being vaccinated) was seen in all age groups after the second dose.

Participants were not reported to have experienced any severe adverse events. The majority of adverse events noted (49%, n=374) were mild (e.g., injection site pain) and a small proportion (19%, n=6) were moderate (e.g., fever, headache). Mild to moderate adverse events resolved within 24 hours.

The data were also submitted to the Drugs Controller General of India (DCGI) to support a pediatric indication as recommended by an independent committee, known as the Subject Expert Committee (SEC), that advises the Indian regulatory agency. Bharat Biotech intends to submit data from the full Phase 3 trial to a peer-reviewed scientific publication soon.

About the Phase 2/3 Trial in Children (BBIL/BBV152/2021)
The seven-month Phase 2/3 open label, multicenter, study enrolled 525 children ages 2 years to 18 from 6 clinical trial sites across India. Conducted between May and July 2021, it was designed to evaluate the safety, reactogenicity and immunogenicity of COVAXIN™ (BBV152) on a two-dose schedule (28 days apart) in three age groups: ages 12-18, ages 6-12, and ages 2-6. Children with prior infection of SARS-CoV-2 were not excluded from the trial.

About COVAXIN™
COVAXIN™ (BBV152) is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). COVAXIN™ (BBV152) is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.

With more than 125 million doses having been administered to adults outside the U.S., COVAXIN™ (BBV152) is currently authorized under emergency use in 17 countries, and applications for emergency use authorization are pending in more than 60 other countries. The World Health Organization (WHO) recently added COVAXIN™ (BBV152) to its list of vaccines authorized for emergency use. And, as many as 110 countries have agreed to mutual recognition of Covid-19 vaccination certificates with India that includes vaccination using COVAXIN™ (BBV152). The trade name, COVAXIN™, has not been evaluated by the FDA.

About Ocugen, Inc. 
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. and Canadian markets. For more information, please visit www.ocugen.com.

About Bharat Biotech 
Bharat Biotech has established an excellent track record of innovation with more than 145 global patents, a wide product portfolio of more than 16 vaccines, 4 bio-therapeutics, registrations in more than 123 countries, and the World Health Organization (WHO) Pre-qualifications. Located in Genome Valley in Hyderabad, India, a hub for the global biotech industry, Bharat Biotech has built a world-class vaccine & bio-therapeutics, research & product development, Bio-Safety Level 3 manufacturing, and vaccine supply and distribution. 

Having delivered more than 4 billion doses of vaccines worldwide, Bharat Biotech continues to lead innovation and has developed vaccines for influenza H1N1, Rotavirus, Japanese Encephalitis, Rabies, Chikungunya, Zika, and the world’s first tetanus-toxoid conjugated vaccine for Typhoid. Bharat’s commitment to global social innovation programs and public-private partnerships resulted in introducing path-breaking WHO pre-qualified vaccines BIOPOLIO®, ROTAVAC®, and Typbar TCV® combatting polio, rotavirus, typhoid infections, respectively. The acquisition of the rabies vaccine facility, Chiron Behring, from GlaxoSmithKline (GSK) has positioned Bharat Biotech as the world’s largest rabies vaccine manufacturer. To learn more about Bharat Biotech, visit www.bharatbiotech.com. 

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include information about qualitative assessments of available data, potential benefits, expectations for clinical trials, and anticipated timing of clinical trial readouts and regulatory submissions, including statements about data published on the preprint server, medRxiv, by Bharat Biotech, which found that COVAXIN™ generated a potentially robust neutralizing antibody response and favorable safety profile in its Phase 2/3 study in pediatric patients, and the potential for this data to support our application to the U.S. Food and Drug Administration (FDA) for emergency use authorization (EUA) of COVAXIN™ in pediatric patients. This information involves risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates; the risk that we may not resolve the current clinical hold on COVAXIN™ in the near term or at all, or that the FDA could make other decisions that adversely impact our ability to advance the development of COVAXIN™ in the United States, and the implications that this clinical hold may have for our request for emergency use authorization for COVAXIN for pediatric use, including the timing and scope of any such authorization; risks associated with preliminary and interim data, including the possibility of unfavorable new clinical trial data and further analyses of existing clinical trial data; the risk that the results of in-vitro studies will not be duplicated in human clinical trials; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from Bharat Biotech’s clinical trials will be published in scientific journal publications and, if so, when and with what modifications; whether the data and results from the preclinical and clinical studies of COVAXIN™, which have been conducted by Bharat Biotech in India, will be accepted by the FDA or otherwise sufficient to support our EUA submission; the size, scope, timing and outcome of any additional trials or studies that we may be required to conduct to support an EUA or biologics license application (BLA); any additional chemistry, manufacturing, and controls information that we may be required to submit to the FDA; whether and when a BLA for COVAXIN™ will be submitted to or approved by the FDA; whether developments with respect to the COVID-19 pandemic will affect the regulatory pathway available for vaccines in the United States, Canada or other jurisdictions; market demand for COVAXIN™ in the United States or Canada; decisions by the FDA or Health Canada impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of COVAXIN™ in the United States or Canada, including development of products or therapies by other companies. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.


Ocugen Contact:  Ken Inchausti Head, Investor Relations & Communications ken.inchausti@ocugen.com Please submit investor-related inquiries to: IR@ocugen.com

Mandatory Holidays and the Value of Flexibility

Posted on by Admin 


	Image Credit J. Lyn (Flickr)

Do Mandatory Holidays Mean Less Freedom and Flexibility for Workers?

 

 

There are many factors to consider when valuing compensation agreements between employees and employers. One standard in a majority of occupations is holiday time off or additional compensation for working. The article that follows visits the subject of federal and national holidays and questions if there is an employee cost to this supposed benefit. It was written by Patrick Carroll who is an Editorial Fellow at the Foundation for Economic Education and holds a degree in Chemical Engineering from the University of Waterloo.

Paul Hoffman – Managing Editor

 

One of the things people tend to appreciate throughout the year, and especially during the Christmas season, is statutory holidays. These days off are taken for granted by many, and few people stop to think about whether they have any drawbacks. But as any good economist will tell you, everything comes with tradeoffs, and holidays are no exception. The trick, then, is to figure out where the cost lies, and who, ultimately, is paying it.

The True Cost of Statutory Holidays

At first blush, it may be tempting to assume that our employers are the ones taking the hit. After all, they are losing productive work hours from their employees. And if all else were equal, that would certainly be correct. Shareholders, ultimately, would bear the cost of this lost productivity.

In most cases, however, things are not that simple. Consider, for example, a world in which there are no statutory holidays. Let’s say there’s a worker in this world who gets twenty paid holidays per year as part of their compensation. Now, let’s say the government introduces ten new statutory holidays, so every employer is now mandated to give their employees a minimum of ten days off per year. What happens?

Clearly, the employer is not going to give their worker ten additional holidays. After all, the government didn’t say it had to be ten more than what the worker was given in the past. They just said it had to be at least ten. The most likely scenario, then, is that the employer will give their worker the ten statutory holidays and ten additional holidays, so that they break even at twenty days per year.

The reason the employer will gravitate toward the same number as before is because of market forces. Time off, like salary, is part of the “price” of labor, and as such, it is determined by supply and demand. Thus, days off tend toward an equilibrium point determined by the market, just as salaries do.

The introduction of statutory holidays can therefore be likened to the introduction of a minimum wage. To the extent that the market “rate” is already higher than the mandated minimum, the new law has no effect on the level of compensation. And since almost all employers give more days off than they are required to by law, it seems clear that market forces, not statutes, are determining the total number of holidays most workers get.

The implication, then, is that the total number of holidays will gravitate toward the market “rate” regardless of whether some of those holidays are mandated or not. Thus, more statutory holidays just means fewer regular holidays. So really, the hidden cost falls entirely on the worker.

The Value of Flexibility

“Fair enough,” you might say. “But if they still break even, what’s the big deal? Isn’t the worker just as well off in either case?” The answer here is no, because while they may get the same total number of days off, their flexibility regarding when they can take those days is significantly curtailed.

Going back to the salary analogy, we’ve already established that if a worker gets paid, say, $20 per hour, a minimum wage of $10 per hour will not make any difference to their total pay. But imagine that instead of simply mandating a minimum of $10 per hour, the government also mandated how that $10 would be spent.

Clearly, this is harmful for the worker. Whereas before they could choose how they spent their entire salary, now they can only choose how they spend part of it, and the part that they can’t control will invariably be spent on things they consider less important than what they would have spent it on themselves. The same logic applies to holidays. If there are ten statutory holidays per year, that’s ten days that can no longer be allocated by the worker.

The reason that flexibility is so important is because the value of time off largely depends on when it’s taken. Imagine your kid gets sick or there is a death in the family. Those are times when days off are more important. But if half of your holidays are fixed by legislative fiat, you lose the ability to use that time when you actually need it. You are forced to “spend” those days on time that is less valuable, which means you can’t spend them when you really need them.

Vacations are also curtailed because of statutory holidays. Since the timing of the mandatory days is rigid and spread out, it’s impossible to use that time off for longer trips that take multiple consecutive days, even though that may be preferable to a series of long weekends.

Of course, if people want to take certain special days off like Thanksgiving or Christmas, they can still choose to do that. But forcing people to take certain days off against their will only pushes them away from their optimal holiday allocation, just like forcing people to spend money on certain things pushes them away from their optimal capital allocation.

If we really want to help workers, then, statutory holidays should be repealed. Said differently, workers should have the freedom to take their time off when they need it most.

 

Suggested Reading:



Holiday Shoppers Troubles are Positive for Investors in Shipping Companies

Since 2008, Monetary Policy Has Cost American Savers about $4 Trillion





Was the Inflation of 1982 Like Today’s?

Can Market Strength Continue Into 2022?

 

Source:

https://mises.org/wire/mandatory-holidays-mean-less-freedom-and-flexibility-workers

 

Stay up to date. Follow us:

 

Release – Ocugen Partner Bharat Biotech Announces Positive Immunogenicity and Safety Data From COVAXIN

Posted on by Admin



Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN™ (BBV152), COVID-19 Candidate Vaccine, in Children 2 – 18 YEARS

 

Research, News, and Market Data on Ocugen

 

  • COVAXIN™ whole virus inactivated vaccine generated broad antibody response comparable to those seen in a large phase 3 trial in adults 18+
  • Adverse events were primarily mild, and no serious adverse events (SAEs) were noted
  • Immunobridging trial demonstrated safety, reactogenicity and immunogenicity of COVAXIN™ in children from 2 years old and up
  • No cases of myocarditis or blood clots were reported, as expected with inactivated vaccines

MALVERN, Pa., Dec. 30, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced today that its partner, Bharat Biotech, posted results from a Phase 2/3 trial conducted in India of candidate vaccine, COVAXIN™ (BBV152), in children, aged 2 – 18 years, demonstrating a robust neutralizing antibody response and favorable safety profile on the pre-print server, medRXiv. Using a two-dose regimen administered 28-days apart, antibody responses in subjects were comparable to adult data from a previous phase 3 study. Those results demonstrated a greater than 93% reduction in severe disease. These pediatric data were the basis of Ocugen’s pediatric Emergency Use Authorization (EUA) submission in the United States for children 2-18 on November 5, 2021.

“These data represent the first positive vaccine data in children as young as two years of age and come at an important time as COVID-19 infections are seeing a spike across the globe,” said Shankar Musunuri, PhD, MBA, Chairman of the Board, Chief Executive Officer and Co-Founder of Ocugen. “The results suggest that COVAXIN™, which is made on the same platform used in traditional polio pediatric vaccines for decades, when administered in a two-dose series to children between 2-18, may offer an option that is safe while delivering a robust immune response.”

In the study, immunogenicity against key COVID-19 proteins was measured using geometric mean titer (GMT), a test that measures the amount of antibodies in the blood in response to the presence of the virus. GMT was measured across three age groups and demonstrated strong immune response after the second dose. There were no serious adverse events such as myocarditis, pericarditis, or blood clots, reported in any of the three age groups.

This immunobridging trial was intended to determine if COVAXIN™ generates the same protective immunity in children as it does in adults. To be considered equivalent, pediatric participants needed to achieve comparable GMT’s to those generated by adults in a large phase 3 clinical trial. At Day 56, across all ages, the mean SARS-CoV-2 antibody GMT was more than 30% higher in children aged 2-18 than the mean GMT from Phase 3 clinical trial involving 25,800 adult subjects aged 18+. These data demonstrate children 2-18 generate antibody response comparable to adults fully vaccinated with COVAXIN™ (BBV152).

The study also showed increased antibody titers against 3 viral antigens (Spike – S1, Receptor Binding Domain – RBD and Nucleocapsid – NP) providing a broad immune response to COVID-19. In each case a more than 4-fold increase in neutralizing antibody titers versus baseline (titers measured in the same participants before being vaccinated) was seen in all age groups after the second dose.

Participants were not reported to have experienced any severe adverse events. The majority of adverse events noted (49%, n=374) were mild (e.g., injection site pain) and a small proportion (19%, n=6) were moderate (e.g., fever, headache). Mild to moderate adverse events resolved within 24 hours.

The data were also submitted to the Drugs Controller General of India (DCGI) to support a pediatric indication as recommended by an independent committee, known as the Subject Expert Committee (SEC), that advises the Indian regulatory agency. Bharat Biotech intends to submit data from the full Phase 3 trial to a peer-reviewed scientific publication soon.

About the Phase 2/3 Trial in Children (BBIL/BBV152/2021)
The seven-month Phase 2/3 open label, multicenter, study enrolled 525 children ages 2 years to 18 from 6 clinical trial sites across India. Conducted between May and July 2021, it was designed to evaluate the safety, reactogenicity and immunogenicity of COVAXIN™ (BBV152) on a two-dose schedule (28 days apart) in three age groups: ages 12-18, ages 6-12, and ages 2-6. Children with prior infection of SARS-CoV-2 were not excluded from the trial.

About COVAXIN™
COVAXIN™ (BBV152) is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). COVAXIN™ (BBV152) is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.

With more than 125 million doses having been administered to adults outside the U.S., COVAXIN™ (BBV152) is currently authorized under emergency use in 17 countries, and applications for emergency use authorization are pending in more than 60 other countries. The World Health Organization (WHO) recently added COVAXIN™ (BBV152) to its list of vaccines authorized for emergency use. And, as many as 110 countries have agreed to mutual recognition of Covid-19 vaccination certificates with India that includes vaccination using COVAXIN™ (BBV152). The trade name, COVAXIN™, has not been evaluated by the FDA.

About Ocugen, Inc. 
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. and Canadian markets. For more information, please visit www.ocugen.com.

About Bharat Biotech 
Bharat Biotech has established an excellent track record of innovation with more than 145 global patents, a wide product portfolio of more than 16 vaccines, 4 bio-therapeutics, registrations in more than 123 countries, and the World Health Organization (WHO) Pre-qualifications. Located in Genome Valley in Hyderabad, India, a hub for the global biotech industry, Bharat Biotech has built a world-class vaccine & bio-therapeutics, research & product development, Bio-Safety Level 3 manufacturing, and vaccine supply and distribution. 

Having delivered more than 4 billion doses of vaccines worldwide, Bharat Biotech continues to lead innovation and has developed vaccines for influenza H1N1, Rotavirus, Japanese Encephalitis, Rabies, Chikungunya, Zika, and the world’s first tetanus-toxoid conjugated vaccine for Typhoid. Bharat’s commitment to global social innovation programs and public-private partnerships resulted in introducing path-breaking WHO pre-qualified vaccines BIOPOLIO®, ROTAVAC®, and Typbar TCV® combatting polio, rotavirus, typhoid infections, respectively. The acquisition of the rabies vaccine facility, Chiron Behring, from GlaxoSmithKline (GSK) has positioned Bharat Biotech as the world’s largest rabies vaccine manufacturer. To learn more about Bharat Biotech, visit www.bharatbiotech.com. 

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include information about qualitative assessments of available data, potential benefits, expectations for clinical trials, and anticipated timing of clinical trial readouts and regulatory submissions, including statements about data published on the preprint server, medRxiv, by Bharat Biotech, which found that COVAXIN™ generated a potentially robust neutralizing antibody response and favorable safety profile in its Phase 2/3 study in pediatric patients, and the potential for this data to support our application to the U.S. Food and Drug Administration (FDA) for emergency use authorization (EUA) of COVAXIN™ in pediatric patients. This information involves risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates; the risk that we may not resolve the current clinical hold on COVAXIN™ in the near term or at all, or that the FDA could make other decisions that adversely impact our ability to advance the development of COVAXIN™ in the United States, and the implications that this clinical hold may have for our request for emergency use authorization for COVAXIN for pediatric use, including the timing and scope of any such authorization; risks associated with preliminary and interim data, including the possibility of unfavorable new clinical trial data and further analyses of existing clinical trial data; the risk that the results of in-vitro studies will not be duplicated in human clinical trials; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from Bharat Biotech’s clinical trials will be published in scientific journal publications and, if so, when and with what modifications; whether the data and results from the preclinical and clinical studies of COVAXIN™, which have been conducted by Bharat Biotech in India, will be accepted by the FDA or otherwise sufficient to support our EUA submission; the size, scope, timing and outcome of any additional trials or studies that we may be required to conduct to support an EUA or biologics license application (BLA); any additional chemistry, manufacturing, and controls information that we may be required to submit to the FDA; whether and when a BLA for COVAXIN™ will be submitted to or approved by the FDA; whether developments with respect to the COVID-19 pandemic will affect the regulatory pathway available for vaccines in the United States, Canada or other jurisdictions; market demand for COVAXIN™ in the United States or Canada; decisions by the FDA or Health Canada impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of COVAXIN™ in the United States or Canada, including development of products or therapies by other companies. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.


Ocugen Contact:  Ken Inchausti Head, Investor Relations & Communications ken.inchausti@ocugen.com Please submit investor-related inquiries to: IR@ocugen.com

Release – Bunker Hill Announces Filing of Updated Technical Report

Posted on by Admin



Bunker Hill Announces Filing of Updated Technical Report

Research, News, and Market Data on Bunker Hill Mining

 

TORONTO, Dec. 29, 2021 (GLOBE NEWSWIRE) — Bunker Hill Mining Corp. (the “Company”) (CSE: BNKR, OTCQB: BHLL) is pleased to announce the filing of an independent Technical Report (“Technical Report”), containing an updated Mineral Resource Estimate for the Bunker Hill Mine in the world-class Silver Valley region of Idaho, USA.

The Technical Report, dated December 29, 2021 and entitled “Technical Report And Preliminary Economic Assessment For Underground Milling and Concentration of Lead, Silver and Zinc at the Bunker Hill Mine, Coeur d’Alene Mining District, Shoshone County, Idaho, USA” with an effective date of November 29, 2021, was prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”).

The Company’s news release (“Prior News Release”) dated November 30, 2021 (entitled “ Bunker Hill Announces Mineral Resource Update, Including 59% Increase in M&I to 1.1 Billion Zinc Eq Pounds at Higher Grades ”) summarizes key results, assumptions and estimates contained in the Technical Report with respect to the updated Mineral Resource Estimate. There are no differences between the key results, assumptions and estimates contained in the Technical Report and the Prior News Release.

The preliminary economic assessment (“PEA”) contained in the Technical Report is unchanged from the PEA contained in the technical report dated June 4, 2021 and entitled, “Technical Report and Preliminary Economic Assessment for Underground Milling and Concentration of Lead, Silver and Zinc at the Bunker Hill Mine, Coeur d’Alene Mining District, Shoshone County, Idaho, USA” with an effective date of April 19, 2021.

The PEA is preliminary in nature and includes inferred mineral resources that are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as mineral reserves, and there is no certainty that the PEA will be realized.

The Technical Report is available on our website at www.bunkerhillmining.com and has been filed on SEDAR under the Company’s issuer profile at www.sedar.com .

QUALIFIED PERSON

Mr. Scott E. Wilson, CPG, President of RDA and a consultant to the Company, is an independent “qualified person” as defined by NI 43-101 and is acting as the qualified person for the Company. He has reviewed and approved the technical information summarized in this news release.

Dr. Deepak Malhotra, SME of Pro Solv LLC, is an independent “qualified person” as defined by NI 43-101 and has approved the metallurgical data utilized in the updated Technical Report and Mineral Resource Estimate.

MineTech developed the mine infrastructure, capital expenditures and operating expenditures related portions of the PEA, as well as portions of the mine plan and operating schedules in coordination with RDA and Pro Solv Consulting, LLC. Robert Todd, P.E. is a Principal of MineTech, a registered engineer in Idaho, consultant to the Company and an independent “qualified person” as defined by NI 43-101.

The qualified persons have verified the information disclosed herein, including the sampling, preparation, security and analytical procedures underlying such information, and are not aware of any significant risks and uncertainties that could be expected to affect the reliability or confidence in the information discussed herein.

ABOUT BUNKER HILL MINING CORP.

Under new Idaho-based leadership the Bunker Hill Mining Corp, intends to sustainably restart and develop the Bunker Hill Mine as the first step in consolidating a portfolio of North American precious-metal assets with a focus on silver. Information about the Company is available on its website, www.bunkerhillmining.com, or within the SEDAR and EDGAR databases.

For additional information contact:

David Wiens, CFA

CFO & Corporate Secretary

+1 208 370 3665

ir@bunkerhillmining.com

Cautionary Statements

Certain statements in this news release are forward-looking and involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, as well as within the meaning of the phrase ‘forward-looking information’ in the Canadian Securities Administrators’ National Instrument 51-102 – Continuous Disclosure Obligations. Forward-looking statements are not comprised of historical facts. Forward-looking statements include estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to the Company, the Company provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information.

Forward looking information in this news release includes, but is not limited to, the Company’s intentions regarding its objectives, goals or future plans and statements. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to: the ability to predict and counteract the effects of COVID-19 on the business of the Company, including but not limited to the effects of COVID-19 on the price of commodities, capital market conditions, restriction on labour and international travel and supply chains; failure to identify mineral resources; failure to convert estimated mineral resources to reserves; the inability to complete a feasibility study which recommends a production decision; the preliminary nature of metallurgical test results; the Company’s ability to restart and develop the Bunker Hill Mine and the risks of not basing a production decision on a feasibility study of mineral reserves demonstrating economic and technical viability, resulting in increased uncertainty due to multiple technical and economic risks of failure which are associated with this production decision including, among others, areas that are analyzed in more detail in a feasibility study, such as applying economic analysis to resources and reserves, more detailed metallurgy and a number of specialized studies in areas such as mining and recovery methods, market analysis, and environmental and community impacts and, as a result, there may be an increased uncertainty of achieving any particular level of recovery of minerals or the cost of such recovery, including increased risks associated with developing a commercially mineable deposit with no guarantee that production will begin as anticipated or at all or that anticipated production costs will be achieved; failure to commence production would have a material adverse impact on the Company’s ability to generate revenue and cash flow to fund operations; failure to achieve the anticipated production costs would have a material adverse impact on the Company’s cash flow and future profitability; delays in obtaining or failures to obtain required governmental, environmental or other project approvals; political risks; changes in equity markets; uncertainties relating to the availability and costs of financing needed in the future; the inability of the Company to budget and manage its liquidity in light of the failure to obtain additional financing, including the ability of the Company to complete the payments pursuant to the terms of the agreement to acquire the Bunker Hill Mine Complex; inflation; changes in exchange rates; fluctuations in commodity prices; delays in the development of projects; capital, operating and reclamation costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry; and those risks set out in the Company’s public documents filed on SEDAR. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Cautionary Note to United States Investors Concerning Estimates of Measured, Indicated and Inferred Resources

This press release has been prepared in accordance with the requirements of the securities laws in effect in Canada, which differ from the requirements of U.S. securities laws. Unless otherwise indicated, all resource and reserve estimates included in this press release have been disclosed in accordance with NI 43-101 and the Canadian Institute of Mining, Metallurgy, and Petroleum Definition Standards on Mineral Resources and Mineral Reserves. NI 43-101 is a rule developed by the Canadian Securities Administrators which establishes standards for all public disclosure an issuer makes of scientific and technical information concerning mineral projects. Canadian disclosure standards, including NI 43-101, differ significantly from the requirements of the United States Securities and Exchange Commission (“SEC”), and resource and reserve information contained in this press release may not be comparable to similar information disclosed by U.S. companies. In particular, and without limiting the generality of the foregoing, the term “resource” does not equate to the term “reserves”. Under U.S. standards, mineralization may not be classified as a “reserve” unless the determination has been made that the mineralization could be economically and legally produced or extracted at the time the reserve determination is made. The SEC’s disclosure standards normally do not permit the inclusion of information concerning “measured mineral resources”, “indicated mineral resources” or “inferred mineral resources” or other descriptions of the amount of mineralization in mineral deposits that do not constitute “reserves” by U.S. standards in documents filed with the SEC. Investors are cautioned not to assume that any part or all of mineral deposits in these categories will ever be converted into reserves. U.S. investors should also understand that “inferred mineral resources” have a great amount of uncertainty as to their existence and great uncertainty as to their economic and legal feasibility. It cannot be assumed that all or any part of an “inferred mineral resource” will ever be upgraded to a higher category. Investors are cautioned not to assume that all or any part of an “inferred mineral resource” exists or is economically or legally mineable. Disclosure of “contained ounces” in a resource is permitted disclosure under Canadian regulations; however, the SEC normally only permits issuers to report mineralization that does not constitute “reserves” by SEC standards as in-place tonnage and grade without reference to unit measures. The requirements of NI 43-101 for disclosure of “reserves” are also not the same as those of the SEC, and reserves disclosed by the Company in accordance with NI 43-101 may not qualify as “reserves” under SEC standards. Accordingly, information concerning mineral deposits contained in our website may not be comparable with information made public by companies that report in accordance with U.S. standards.

Capstone Green Energy (NASDAQ:CGRN) to Provide its 600kW Energy Solution System to a Food Processing Facility in Mali

Posted on by Admin

 


Capstone Green Energy (NASDAQ:CGRN) to Provide its 600kW Energy Solution System to a Food Processing Facility in Mali

Research, News, and Market Data on Capstone Green Energy

 

On-site Power System Will Be Less Expensive, More Reliable & More Environmentally Friendly

VAN NUYS, CA / ACCESSWIRE / December 29, 2021 / Capstone Green Energy Corporation (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN), (“Capstone,” the “Company,” “we” or “us”), a global leader in carbon reduction and on-site resilient green energy solutions, today announced that it has received an order for a 600 kilowatt (kW), C600S energy solution system, to be installed at a remote food processing facility in Bamako, Mali. The order was secured through the Capstone Green Energy Direct Sales Solutions Team. The system, which will provide power to the site’s all-electric equipment, is expected to be commissioned in May 2022.

Like many land-locked countries, Mali relies on expensive, “dirty,” fuels like diesel and heavy fuel oil. By contrast, the Capstone energy system will use liquefied petroleum gas (LPG), which is a less expensive and more environmentally-friendly fuel alternative.

“This project serves as a model for other industrial customers and power companies, showing they can quickly benefit from LPG as an alternative fuel,” said Gorgui Ndoye, Business Development Director for Capstone Green Energy. “There is growing interest in LPG in many regions around the globe, especially in Africa, South America, the Caribbean, and some parts of Asia, where availability of the fuel has increased significantly in the past ten years.”

Since Capstone microturbine green energy systems are highly reliable, the on-site system will also address issues of load shedding and blackouts the facility currently experiences with utility power. They also require very little maintenance compared to other on-site power technologies like diesel generators, which further improves power availability and cost savings.

“Food manufacturing facilities have among the greatest need for power reliability since outages can cause spoilage and lost product,” said Darren Jamison, Chief Executive Officer of Capstone Green Energy. “That added operational security plus the significant cost savings in fuel can have a major positive impact on a company’s bottom line. When the cleaner fuel and low emissions impact are also factored in, the benefits of microturbine-based, on-site power generation are undeniable.”

About Capstone Green Energy

Capstone Green Energy (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN) is a leading provider of customized microgrid solutions and on-site energy technology systems focused on helping customers around the globe meet their environmental, energy savings, and resiliency goals. Capstone Green Energy focuses on four key business lines. Through its Energy as a Service (EaaS) business, it offers rental solutions utilizing its microturbine energy systems and battery storage systems, comprehensive Factory Protection Plan (FPP) service contracts that guarantee life-cycle costs, as well as aftermarket parts. Energy Generation Technologies (EGT) are driven by the Company’s industry-leading, highly efficient, low-emission, resilient microturbine energy systems offering scalable solutions in addition to a broad range of customer-tailored solutions, including hybrid energy systems and larger frame industrial turbines. The Energy Storage Solutions (ESS) business line designs and installs microgrid storage systems creating customized solutions using a combination of battery technologies and monitoring software. Through Hydrogen & Sustainable Products (H2S), Capstone Green Energy offers customers a variety of hydrogen products, including the Company’s microturbine energy systems.

For customers with limited capital or short-term needs, Capstone offers rental systems; for more information, contact: rentals@CGRNenergy.com. To date, Capstone has shipped over 10,000 units to 83 countries and estimates that, in FY21, it saved customers over $217 million in annual energy costs and approximately 397,000 tons of carbon. Total savings over the last three years are estimated to be approximately $698 million in energy savings and approximately 1,115,100 tons of carbon savings.

For more information about the Company, please visit www.CapstoneGreenEnergy.com. Follow Capstone Green Energy on Twitter, LinkedIn, Instagram, Facebook, and YouTube.

Cautionary Note Regarding Forward-Looking Statements

This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding expectations for green initiatives and execution on the Company’s growth strategy and other statements regarding the Company’s expectations, beliefs, plans, intentions, and strategies. The Company has tried to identify these forward-looking statements by using words such as “expect,” “anticipate,” “believe,” “could,” “should,” “estimate,” “intend,” “may,” “will,” “plan,” “goal” and similar terms and phrases, but such words, terms and phrases are not the exclusive means of identifying such statements. Actual results, performance and achievements could differ materially from those expressed in, or implied by, these forward-looking statements due to a variety of risks, uncertainties and other factors, including, but not limited to, the following: the ongoing effects of the COVID-19 pandemic; the availability of credit and compliance with the agreements governing the Company’s indebtedness; the Company’s ability to develop new products and enhance existing products; product quality issues, including the adequacy of reserves therefor and warranty cost exposure; intense competition; financial performance of the oil and natural gas industry and other general business, industry and economic conditions; the Company’s ability to adequately protect its intellectual property rights; and the impact of pending or threatened litigation. For a detailed discussion of factors that could affect the Company’s future operating results, please see the Company’s filings with the Securities and Exchange Commission, including the disclosures under “Risk Factors” in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

CONTACT:
Capstone Green Energy
Investor and investment media inquiries:
818-407-3628
ir@CGRNenergy.com

SOURCE: Capstone Green Energy Corporation

Euroseas (ESEA) – Positive Impact from Two Feeders Fixed At Attractive Rates

Posted on by Admin

Wednesday, December 29, 2021

Euroseas (ESEA)
Positive Impact from Two Feeders Fixed At Attractive Rates

Euroseas Ltd. provides ocean-going transportation services worldwide. The company owns and operates containerships that transport dry and refrigerated containerized cargoes, including manufactured products and perishables; and drybulk carriers that transport iron ore, coal, grains, bauxite, phosphate, and fertilizers. As of March 31, 2017, it had a fleet of seven containerships; and six drybulk carriers, including three Panamax drybulk carriers, one Handymax drybulk carrier, one Kamsarmax drybulk carrier, and one Ultramax drybulk carrier. The company was founded in 2005 and is based in Maroussi, Greece.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Two new feeder fixtures indicate firm container market. Two 2,556 TEU feeders, the Corfu and Evridiki G, were locked up on time charters for at least three years at very attractive TCE rates of $40.0k/day. The new feeder rates are very positive when considering the recent four-year time charter on the Oakland intermediate at a TCE rate of $42.0k/day.

    No change to our 2021 EBITDA estimate of $53.9 million based on TCE rates of $18.6k/day, but positive impact on 2022 EBITDA estimate.  We are moving our 2022 EBITDA estimate to $109.4 million from $101.6 million based on TCE rates of $28.5k/day, up from $27.0k/day …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Research – Capstone Green Energy to Provide its 600kW Energy Solution System to a Food Processing Facility in Mali

Posted on by Admin

 


Capstone Green Energy (NASDAQ:CGRN) to Provide its 600kW Energy Solution System to a Food Processing Facility in Mali

Research, News, and Market Data on Capstone Green Energy

 

On-site Power System Will Be Less Expensive, More Reliable & More Environmentally Friendly

VAN NUYS, CA / ACCESSWIRE / December 29, 2021 / Capstone Green Energy Corporation (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN), (“Capstone,” the “Company,” “we” or “us”), a global leader in carbon reduction and on-site resilient green energy solutions, today announced that it has received an order for a 600 kilowatt (kW), C600S energy solution system, to be installed at a remote food processing facility in Bamako, Mali. The order was secured through the Capstone Green Energy Direct Sales Solutions Team. The system, which will provide power to the site’s all-electric equipment, is expected to be commissioned in May 2022.

Like many land-locked countries, Mali relies on expensive, “dirty,” fuels like diesel and heavy fuel oil. By contrast, the Capstone energy system will use liquefied petroleum gas (LPG), which is a less expensive and more environmentally-friendly fuel alternative.

“This project serves as a model for other industrial customers and power companies, showing they can quickly benefit from LPG as an alternative fuel,” said Gorgui Ndoye, Business Development Director for Capstone Green Energy. “There is growing interest in LPG in many regions around the globe, especially in Africa, South America, the Caribbean, and some parts of Asia, where availability of the fuel has increased significantly in the past ten years.”

Since Capstone microturbine green energy systems are highly reliable, the on-site system will also address issues of load shedding and blackouts the facility currently experiences with utility power. They also require very little maintenance compared to other on-site power technologies like diesel generators, which further improves power availability and cost savings.

“Food manufacturing facilities have among the greatest need for power reliability since outages can cause spoilage and lost product,” said Darren Jamison, Chief Executive Officer of Capstone Green Energy. “That added operational security plus the significant cost savings in fuel can have a major positive impact on a company’s bottom line. When the cleaner fuel and low emissions impact are also factored in, the benefits of microturbine-based, on-site power generation are undeniable.”

About Capstone Green Energy

Capstone Green Energy (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN) is a leading provider of customized microgrid solutions and on-site energy technology systems focused on helping customers around the globe meet their environmental, energy savings, and resiliency goals. Capstone Green Energy focuses on four key business lines. Through its Energy as a Service (EaaS) business, it offers rental solutions utilizing its microturbine energy systems and battery storage systems, comprehensive Factory Protection Plan (FPP) service contracts that guarantee life-cycle costs, as well as aftermarket parts. Energy Generation Technologies (EGT) are driven by the Company’s industry-leading, highly efficient, low-emission, resilient microturbine energy systems offering scalable solutions in addition to a broad range of customer-tailored solutions, including hybrid energy systems and larger frame industrial turbines. The Energy Storage Solutions (ESS) business line designs and installs microgrid storage systems creating customized solutions using a combination of battery technologies and monitoring software. Through Hydrogen & Sustainable Products (H2S), Capstone Green Energy offers customers a variety of hydrogen products, including the Company’s microturbine energy systems.

For customers with limited capital or short-term needs, Capstone offers rental systems; for more information, contact: rentals@CGRNenergy.com. To date, Capstone has shipped over 10,000 units to 83 countries and estimates that, in FY21, it saved customers over $217 million in annual energy costs and approximately 397,000 tons of carbon. Total savings over the last three years are estimated to be approximately $698 million in energy savings and approximately 1,115,100 tons of carbon savings.

For more information about the Company, please visit www.CapstoneGreenEnergy.com. Follow Capstone Green Energy on Twitter, LinkedIn, Instagram, Facebook, and YouTube.

Cautionary Note Regarding Forward-Looking Statements

This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding expectations for green initiatives and execution on the Company’s growth strategy and other statements regarding the Company’s expectations, beliefs, plans, intentions, and strategies. The Company has tried to identify these forward-looking statements by using words such as “expect,” “anticipate,” “believe,” “could,” “should,” “estimate,” “intend,” “may,” “will,” “plan,” “goal” and similar terms and phrases, but such words, terms and phrases are not the exclusive means of identifying such statements. Actual results, performance and achievements could differ materially from those expressed in, or implied by, these forward-looking statements due to a variety of risks, uncertainties and other factors, including, but not limited to, the following: the ongoing effects of the COVID-19 pandemic; the availability of credit and compliance with the agreements governing the Company’s indebtedness; the Company’s ability to develop new products and enhance existing products; product quality issues, including the adequacy of reserves therefor and warranty cost exposure; intense competition; financial performance of the oil and natural gas industry and other general business, industry and economic conditions; the Company’s ability to adequately protect its intellectual property rights; and the impact of pending or threatened litigation. For a detailed discussion of factors that could affect the Company’s future operating results, please see the Company’s filings with the Securities and Exchange Commission, including the disclosures under “Risk Factors” in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

CONTACT:
Capstone Green Energy
Investor and investment media inquiries:
818-407-3628
ir@CGRNenergy.com

SOURCE: Capstone Green Energy Corporation